Introduction
Gynandroblastoma is a rare mixed sex cord-stromal tumour characterised by the presence of both male (Sertoli and/or Leydig cells) and female (granulosa cells) components. 1 It occurs in the ovary or the testis, although only very few testicular examples have been reported. 2 The female components of ovarian gynandroblastoma are granulosa cell tumour (GCT) of either juvenile (jGCT) or adult-type (aGCT), while the male elements consist of Sertoli cell tumour (SCT) or Sertoli-Leydig cell tumour.(SLCT). 3 Clinically, gynandroblastomas may cause virilisation as a result of endocrine androgen secretion by tumours, 4 but oestrogenic manifestations have also been reported.
Although patients are usually diagnosed at stage I, some ovarian gynandroblastomas have metastasised, so they are considered to be of low malignant potential. 7 Therefore, patients with gynandroblastoma sometimes receive chemotherapy with carboplatin and paclitaxel on the basis of histological similarity of the tumour to GCT and SLCT; 8 however, the rationale for this clinical practice is lacking, as it is unclear whether gynandroblastoma is related pathogenetically to GCT or SLCT. Recent studies have shown that approximately 95% of aGCTs harbour the p.C134W mutation in FOXL2, [9] [10] [11] [12] [13] while in-frame duplications affecting the pleckstrin-homology (PH) domain of AKT1 and/or activating AKT1 mutations were identified in 87.5% (14 of 16) of jGCTs in girls aged less than 15 years.
14 Furthermore, approximately half or more of ovarian SLCTs harbour mutations in the RNase IIIb domain of DICER1 [15] [16] [17] [18] that skew the maturation of microRNAs. 16, 19 No FOXL2 p.C134W mutation was identified in seven ovarian gynandroblastomas analysed by Oparka et al. 20 In contrast, Conlon et al. analysed five gynandroblastomas and discovered mutually exclusive FOXL2 p.C134W mutations and DICER1 mutations in two and three cases, respectively. 18 The discrepancy between these two studies highlights the need to investigate the mutational status of DICER1 and FOXL2 in a centrally reviewed cohort of cases diagnosed as gynandroblastoma.
Although commonly used by pathologists for a neoplasm comprised of at least 10% of both male and female sex cord elements, the term gynandroblastoma is no longer used in the 2014 World Health Organisation (WHO) classification of tumours of the female reproductive organs. 21 The rationale to remove it from the classification is unclear, and there is no category that encompasses tumours composed of both male and female sex cord elements. In order to address whether ovarian gynandroblastoma shares key genomic features with SLCT or GCT, we performed mutational analysis of FOXL2, DICER1 and AKT1 and analysed FoxL2 protein expression in a cohort of 16 ovarian gynandroblastomas.
Materials and methods

P A T I E N T S A N D S A M P L E S
Sixteen ovarian gynandroblastomas were obtained from archives of three authors (W.G.M., F.K. and C.B.G.). Approval for tissue use was gained from local ethical committees with research ethics boardapproved protocols for mutation analysis (H02-01411, Whole scrolls of tumour blocks were used for DNA extraction. To isolate tumour separately from the different histological components, tissue macrodissection was performed manually on unstained slides based on an adjacent haematoxylin and eosin (H&E)-stained section marked by a pathologist. Samples were deparaffinised and genomic DNA was purified using QIAamp DNA FFPE Tissue Kit (Qiagen, Valencia, CA, USA), following the manufacturer's protocol.
A TaqMan real-time polymerase chain reaction (PCR)-based allelic discrimination assay was performed as described previously 22 to genotype the FOXL2 c.402C?G mutation using the following primers: 5 0 -GCGCAAGGGCAACTACTG-3 0 (forward) and 
S A N G E R S E Q U E N C I N G
M13-tagged PCR primer sets were designed to amplify regions of the RNase IIIb domain of DICER1 or the pleckstrin-homology domain of AKT1. Initial PCR amplification was performed with Platinum Taq DNA polymerase high fidelity (Thermo Fisher Scientific, Carlsbad, CA, USA). The primers included Dicer1_P2 and Dicer1_TM primer sets described above that sequenced E1705/D1709 sites and D1810/E1813 sites, respectively, and AKT1 primer set: 5 0 -GGCCCAA-CACCTTCATCA-3 0 (sense) and 5 0 -TCCTCAGGAGTCTC-CACAT-3 0 (anti-sense). To identify samples with duplications of the AKT1 PH domain, PCR products of AKT1 amplicons were resolved by gel electrophoresis with a case of jGCT harbouring duplication of the AKT1 PH domain as a positive control. PCR products of PCR amplicons were purified using EXoSAP-IT (USB products; Affymetrix, Santa Clara, CA, USA). Sequencing reactions were performed in both forward and reverse directions using M13 primers and the ABI BigDYe terminator version 3.1 cycle sequencing kit (Applied Biosystems). Amplified products were then sequenced using an ABI Prism 3130x Genetic Analyzer by Source Bioscience (Cambridge, UK).
I M M U N O H I S T O C H E M I S T R Y ( I H C )
FOXL2 IHC was performed using primary goat polyclonal FOXL2 antiserum (1:200; Imgenex, Littleton, Co, USA) and a secondary antibody (1:300, unconjugated rabbit anti-goat; Jackson ImmunoResearch Laboratories, West Grove, PA, USA). Assessment of FoxL2 IHC was performed by a gynaecological pathologist (A.N.K.). Any nuclear staining was considered positive.
S T A T I S T I C A L A N A L Y S I S
Student's t-test was used to evaluate significant differences between two groups. Fisher's exact test was used in the analysis of contingency tables. A P < 0.05 was considered significant.
Results
C H A R A C T E R I S T I C S O F O V A R I A N G Y N A N D R O B L A S T O M A S
The clinical information of all 16 ovarian gynandroblastoma patients is summarised in Table 1 . The median age of all patients was 24.5 years (range = 14-80). Histological review showed that 94% (15 of 16) of cases contained SLCT as their male components, including two cases that also had a component of sex cord-stromal tumour, unclassified (case 5) or SCT (case 9). The remaining one case had only SCT as the male component (case 10). Among the 15 cases with a SLCT component, 47% (seven of 15) of the cases had welldifferentiated SLCT, whereas the other eight cases contained SLCT of moderate or poor differentiation, one of which displayed heterologous intestinal-type mucinous glands (case 4, Figure 1 ). Regarding female components, 62.5% (10 of 16) and 43.8% (seven of 16) of the cases contained variable amounts of jGCT or aGCT components, respectively, including a single tumour that had an aGCT component with microscopic foci of jGCT (case 9). The median age of patients with gynandroblastoma with either a jGCT or aGCT component were 23 and 24.5 years, respectively. Representative H&E images are shown in Figure 1 Targeted next-generation sequencing of genomic sequence spanning somatic DICER1 hot-spot mutations within RNase IIIb domain showed that 19% (three of 16) of the cases had heterozygous DICER1 mutations at one of the key metal binding sites, comprising p.E1705V, p.E1813K and p.D1810H (Table 1 ). An additional mutation, p.W1831X, was identified along with the DICER1 p.E1705V hot-spot mutation in case 3, but its impact on DICER1 function is unclear. These mutations were validated further by Sanger sequencing.
DICER1 mutation tended to occur in younger patients with a median age at diagnosis of 20 years (range = 15-26) compared to 26.5 years for gynandroblastomas without DICER1 mutation (range = 14-80) ( Figure 3A , P = 0.25). All three gynandroblastomas with DICER1 mutations contained moderately or poorly differentiated SLCT as male components, including one case with heterologous mucinous elements, representing 38% (three of eight) of cases containing moderately/poorly differentiated SLCT ( Figure 3B) . Furthermore, they all contained jGCT, but not aGCT, as their female components, representing 38% (three of eight) of cases with SLCT and jGCT components ( Figure 3C ). Further analysis of the macrodissected jGCT and SLCT components demonstrated that all three cases exhibited the same heterozygous DICER1 mutation in both components.
Mutational analysis of FOXL2 at the c.402 site (p.C134) by Taqman allelic discrimination PCR assay revealed that all 16 gynandroblastoma had wild-type FoxL2 (Table 1 ). In addition, no duplication of the PH domain of AKT1 was identified in any case.
F O X L 2 E X P R E S S I O N I N G Y N A N D R O B L A S T O M A B Y I M M U N O H I S T O C H E M I S T R Y
FOXL2 nuclear expression was present in both the male and female components of all 16 gynandroblastomas. In most cases staining was diffuse, with most of the tumour nuclei being positive. Representative images of FOXL2 immunostaining are shown in Figures 1 and 2 .
Discussion
Gynandroblastoma is a rare primary ovarian tumour with morphological evidence of both male and female sex cord differentiation. Our study analysed the molecular features of a cohort of 16 ovarian gynandroblastomas. Nineteen per cent (three of 16) of the cases had DICER1 hot-spot mutations at the key metal binding sites that are believed to drive oncogenesis in more than half of ovarian SLCTs, 17, 19, 23 in particular moderately and poorly differentiated neoplasms, which often comprise a morphological spectrum; in contrast, all well-differentiated SLCTs studied so far are wildtype DICER1. 19, 23 Our study demonstrated that 38% (three of eight) of gynandroblastomas with a component of moderately/poorly differentiated SLCT had DICER1 mutations, while none of seven gynandroblastomas with well-differentiated SLCT exhibited a mutation, suggesting that some gynandroblastomas may be morphological variants of SLCT. All three gynandroblastomas in our series with a DICER1 mutation exhibited a mixture of moderately/ poorly differentiated SLCT and jGCT. This is interesting, given that areas resembling jGCT may be present in moderately and poorly differentiated SLCTs (personal observations, W.G.M.). de Kock et al. 23 identified DICER1 mutations in all 30 moderately and poorly differentiated SLCTs, two of which had areas resembling jGCT. Oost et al. 24 reported four ovarian sex cord-stromal tumours in patients with proven or probable germline mutations in DICER1, three of which showed a similar appearance characterised by marked architectural and cytological heterogeneity, including sertoliform, jGCT-like and unclassifiable elements. Furthermore, Conlon et al. identified DICER1 mutations in two of five gynandroblastomas but did not describe areas specifically resembling jGCT. 12 Schultz et al. gynandroblastomas with jGCT in their study, but did not provide details of the pathological features. 25 Therefore, these observations suggest that gynandroblastomas with a component of moderately/poorly differentiated SLCT and jGCT are essentially SLCTs, with areas showing morphological mimicry of jGCT. In our study, the DICER1 hot-spot mutations were demonstrated in both the SLCT and jGCT components in all three gynandroblastomas cases associated with the mutation. This supports the concept that the two components represent morphological divergence within a single neoplastic lesion. DICER1 is an endoribonuclease that controls the production of microRNAs; it remains unclear how DICER1 mutation drives the development of ovarian SLCT. We have reported previously that DICER1 mutation in SLCT was associated with the reduced expression of CYP19A1 (aromatase) that controls oestrogen synthesis from testosterone and differentiation of somatic cell lineages in the ovary. 19, 26 A recent report also confirmed that DICER1 mutation is associated with an increased testosterone level in patients with ovarian SLCT. 27 Therefore it is plausible that, by decreasing aromatase expression and/or skewing global gene expression, DICER1 mutation alters the fate of the cell of origin (e.g. granulosa cells of primordial or pre-ovulatory follicles) towards Sertoli-like cells in SLCT and gynandroblastoma, which can then stimulate androgen production in luteinised stromal (Leydig) cells. It is possible that additional genetic or epigenetic events occurring in certain cells during the oncogenic transformation may prevent their cell fate transition into male cell types and become jGCT. Future studies comparing genomic alternations in both SLCT and jGCT components will improve our understanding of the oncogenic process in gynandroblastomas.
In the study by Conlon et al., FOXL2 p.C134W mutations were identified in two of five gynandroblastomas, and these were mutually exclusive with DICER1 mutations. 12 The authors did not describe the morphological features of these cases in detail, but given that the FOXL2 mutation is considered to be a sensitive and specific molecular marker of aGCT it is possible that these neoplasms essentially represent aGCTs with areas mimicking SCT or SLCT. Our current study and that of Oparka et al. 20 did not identify a FOXL2 p.C134W mutation in any gynandroblastomas, although 37.5% (six of 16) of the neoplasms in our series displayed an aGCT component. This suggests that the oncogenic process of gynandroblastomas containing an aGCT component is fundamentally different from aGCT, in which the near-universal FOXL2 p.C134W mutation appears to drive tumour development. Supporting this, patients with gynandroblastomas with a component of aGCT in the present study were much younger (median age = 24.5 years) in comparison to pure aGCT (median age = 54 years), 13 suggesting that the unique cellular and extracellular microenvironment present only in older patients may be required for FOXL2 mutation-driven transformation.
In one study, in-frame duplications affecting the PH domain of AKT1 were identified in most jGCTs occurring in girls aged less than 15 years.
14 In our study, none of the gynandroblastomas exhibited duplication in the PH domain of AKT1, suggesting that the pathogenesis of gynandroblastomas containing a jGCT component is fundamentally different from pure jGCT.
FOXL2 was expressed in both the male and female components of all 16 gynandroblastomas in our study. Our group has previously examined FOXL2 immunohistochemical expression in a large series of ovarian sex cord-stromal tumours. 28 Positive nuclear staining was present in 95 of 119 (80%) sex cordstromal tumours, including greater than 95% of aGCTs, jGCTs, fibromas and sclerosing stromal tumours and 50% (20 of 40) of SLCTs, but not in any non-sex cord-stromal tumours tested (n = 368), suggesting that FOXL2 is a relatively sensitive and highly specific marker of a sex cord-stromal tumour but is of little or no value in distinguishing between the various neoplasms in this group. Therefore, our study suggests strongly that gynandroblastomas composed of SLCT and jGCT are morphological variants of SLCT. The molecular basis of gynandroblastomas containing an aGCT component appears to be different from that of pure aGCT, which are usually found in older patients, and contain FOXL2 mutations in almost all cases. As the term 'gynandroblastoma' is no longer used in the 2014 WHO classification of tumours of the female reproductive organs, we recommend that gynandroblastomas composed of SLCT and jGCT can be classified under SLCT. Identifying pathogenic mutations in SLCT without the DICER1 mutation may provide tools to assess the genomic similarity between gynandroblastomas and SLCT without DICER1 mutations. Future studies of larger cohorts of centrally reviewed cases will be necessary to validate our findings.
